The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia
Abstract
OBJECTIVES: The pregabalin dose-response for pain, Patient Global Impression of Change (PGIC), and sleep quality measures in painful diabetic peripheral neuropathy (pDPN), postherpetic neuralgia (PHN), and fibromyalgia (FM) is relevant for physicians treating these patients. This analysis aimed to demonstrate the dose-response of pregabalin for each indication and describe the onset (incidence), onset/continuation (prevalence), and resolution of adverse events (AEs) occurring during treatment. METHODS: dose-response model examined the dose-response of pregabalin for pain, PGIC, and sleep quality. Safety assessments included onset and prevalence of common AEs each week, and resolution in the first 2 months of treatment. RESULTS: In all indications, the likelihood of patients experiencing pain relief and improvements in PGIC and sleep quality increased in a dose-dependent manner with increasing doses. In all indications, new incidences of dizziness and somnolence were highest after 1 week of treatment, with few subsequent new reports at a given dose. Prevalence rates decreased steadily after 1 week of treatment. In FM, new onset weight gain emerged 6-8 weeks following treatment; prevalence rates generally increased then remained steady over time. With the exception of weight gain, many AEs resolved in month 1. CONCLUSION: The dose-response of pregabalin for pain, PGIC, and sleep quality was demonstrated, highlighting the benefit of achieving the maximum recommended dose of 300 mg/day for pDPN, 300-600 mg/day for PHN, and 300-450 mg/day for FM. Common AEs are generally seen within 1 week of starting treatment, with few subsequent new reports at a given dose. New onset weight gain occurs after 6 weeks of treatment, reinforcing the need for regular monitoring of weight.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At present, among pharmacological options, pregabalin588–598 and duloxetine594,595,599,600 are oral agents that have received regulatory approval for the treatment of neuropathic pain associated with DPN by the FDA and are effective for DPN pain reduction when using patient-reported outcomes.547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [592]
Citations
Cites
The american college of rheumatology 1990 criteria for the classification of fibromyalgia
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330203 · Cited by 9,563 · cited 1×
“Patients in the FM trials had a primary diagnosis defined by the American College of Rheumatology 1990 criteria of widespread pain present for ≥3 months and pain in ≥11 of 18 tender point sites [26].”
MethodThe short-form McGill pain questionnaire
Melzack, R. (1987) · Pain · doi:10.1016/0304-3959(87)91074-8 · Cited by 4,368
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126 · cited 1×
“individual patient response and tolerability [3,4].”
Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial
Dworkin, R. H., Corbin, A. E., Young, J. P., Sharma, U., LaMoreaux, L., Bockbrader, H., Garofalo, E. A., & Poole, R. M. (2003) · Neurology · doi:10.1212/01.wnl.0000055433.55136.55 · Cited by 768 · cited 1×
“1008–149 [21] (Placebo, n = 96) 12-week (11-week, BID) 150 (n = 99) 75 150 150 150 150 150 150 150 150 150 300 (n = 112) 75 150 150 225 225 225 300 300 300 300 600 (n = 88) 75 150 225 300 400 500 600 600 600 600 1008–173 [22] (Placebo, n = 30) 12-week (11-week, BID) 150 (n = 34) 75 150 150 150 150 150 150 150 150 150…”
Pregabalin for acute and chronic pain in adults
Moore, R. A., Straube, S., Wiffen, P. J., Derry, S., & McQuay, H. J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007076.pub2 · Cited by 762 · cited 1×
“pDPN, PHN, and patients with FM across the recommended dose range [8,9].”
BackgroundRosenstock, J., Tuchman, M., LaMoreaux, L., & Sharma, U. (2004) · Pain · doi:10.1016/j.pain.2004.05.001 · Cited by 725 · cited 1×
“pDPN trials for efficacy and safety analyses 1008–014 [12] (Placebo, n = 85) 6-week (4-week, TID) 150 (n = 79) 25 25 50 50 50 75 75 75 100 150 600 (n = 82) 100 100 200 200 200 300 300 300 400 600 1008–029 [11] (Placebo, n = 97) 5-week (4-week, TID) 75 (n = 77) 75 75 75 75 75 75 75 75 75 75 300 (n = 81) 300 300 300 300…”
Crofford, L. J., Rowbotham, M. C., Mease, P. J., Russell, I. J., Dworkin, R. H., Corbin, A. E., Young, J. P., LaMoreaux, L. K., Martin, S. A., Sharma, U., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20983 · Cited by 654 · cited 1×
“1008–149 [21] (Placebo, n = 96) 12-week (11-week, BID) 150 (n = 99) 75 150 150 150 150 150 150 150 150 150 300 (n = 112) 75 150 150 225 225 225 300 300 300 300 600 (n = 88) 75 150 225 300 400 500 600 600 600 600 1008–173 [22] (Placebo, n = 30) 12-week (11-week, BID) 150 (n = 34) 75 150 150 150 150 150 150 150 150 150…”
Bril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., Feldman, E., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166ebe · Cited by 634
Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial
Lesser, H., Sharma, U., LaMoreaux, L., & Poole, R. M. (2004) · Neurology · doi:10.1212/01.wnl.0000145767.36287.a1 · Cited by 570 · cited 1×
“pDPN trials for efficacy and safety analyses 1008–014 [12] (Placebo, n = 85) 6-week (4-week, TID) 150 (n = 79) 25 25 50 50 50 75 75 75 100 150 600 (n = 82) 100 100 200 200 200 300 300 300 400 600 1008–029 [11] (Placebo, n = 97) 5-week (4-week, TID) 75 (n = 77) 75 75 75 75 75 75 75 75 75 75 300 (n = 81) 300 300 300 300…”
Sabatowski, R., Gálvez, R., Cherry, D. A., Jacquot, F., Vincent, E., Maisonobe, P., & Versavel, M. (2004) · Pain · doi:10.1016/j.pain.2004.01.001 · Cited by 527 · cited 1×
“1008–149 [21] (Placebo, n = 96) 12-week (11-week, BID) 150 (n = 99) 75 150 150 150 150 150 150 150 150 150 300 (n = 112) 75 150 150 225 225 225 300 300 300 300 600 (n = 88) 75 150 225 300 400 500 600 600 600 600 1008–173 [22] (Placebo, n = 30) 12-week (11-week, BID) 150 (n = 34) 75 150 150 150 150 150 150 150 150 150…”
Research works printed but not linked: 9
- Mease PJ, 2008, J Rheumatol, 35, 502
- Pfizer Inc. Study 1008-040. Data on file
- Pfizer Inc. Study 1008-173. Data on file
- Pfizer Inc. Study 1008-030. Data on file
- Pfizer Inc. Study 1008-132. Data on file
- Gore M, 2010, Am J Manag Care, 16, S144
- Sanchez RJ, 2012, Am J Pharm Benefits, 4, 158
- Pfizer Inc, 2015, Mu sigma pregabalin dosing by indication and strength
- Parsons B, 2015, J Pain Res, 8, 303
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Pregabalin for neuropathic pain in primary care settings: recommendations for dosing and titration
Freynhagen, R., Baron, R., Kawaguchi, Y., Malik, R. A., Martire, D. L., Parsons, B., Rey, R., Schug, S. A., Jensen, T. S., Tölle, T. R., et al. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2020.1857992 · Cited by 31
“been associated with improved sleep quality [37], including more time spent in restful rapid eye movement sleep, which is the most restorative sleep phase [56].”
BackgroundSelf-citationPeng, Z., Guo, J., Zhang, Y., Guo, X., Huang, W., Li, Y., Yan, Z., Guo, N., Ke, D., Chen, L., et al. (2022) · Pain and Therapy · doi:10.1007/s40122-022-00355-3 · Cited by 22
“Several retrospective database analyses have reported the administration of low-dose pregabalin in patients with PHN [13].”
BackgroundThe use of antineuropathic medications for the treatment of chronic pain
Urits, I., Li, N., Berardino, K., Artounian, K., Bandi, P., Jung, J. W., Kaye, R. J., Manchikanti, L., Kaye, A. M., Simopoulos, T. T., et al. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.08.007 · Cited by 23
dos Santos, G. G. L., Oliveira, A. L. L., Santos, D. S., Santo, R. F. D. E., Silva, D. N., Juíz, P. J. L., Soares, M. B. P., & Villarreal, C. F. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118755 · Cited by 21
“Therapeutic approaches to chemotherapy-induced painful neuropathy control have been based on evidence from other neuropathies treatment such as diabetes and post-herpetic [17,18], but these practices have been found to be unsatisfactory.”
Background
Metadata
- Authors
- Arnold, L. M., McCarberg, B. H., Clair, A. G., Whalen, E., Thomas, N., Jorga, A., Pauer, L., Vissing, R., & Park, P. W.
- Affiliations
- University of Cincinnati (US)
- University of California San Diego (US)
- Pfizer (United States) (US)
- Corresponding author
- Park, Peter W.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2017-10-16
- Volume
- 129
- Issue
- 8
- Pages
- 921-933
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W2761247062
- Cited by
- 27
- References
- 38
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 3
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Postgraduate Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Keywords
- pregabalin, dose-response relationship, diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, analgesia, Patient Global Impression of Change, sleep quality, adverse events, dizziness, sleepiness, weight gain, drug safety
- MeSH terms
- Pregabalin, Adolescent, Adult, Aged, Aged, 80 and over, Analgesics, Diabetic Neuropathies, Dose-Response Relationship, Drug, Female, Fibromyalgia, Humans, Male, Middle Aged, Sleep, Neuralgia, Postherpetic, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. https://app.cochat.ai/papers/10.1080/00325481.2017.1384691
- The paper
- Arnold, L. M., McCarberg, B. H., Clair, A. G., Whalen, E., Thomas, N., Jorga, A., Pauer, L., Vissing, R., & Park, P. W. (2017). Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. Postgraduate Medicine. https://doi.org/10.1080/00325481.2017.1384691
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.